Iovance Biotherapeutics shares rise 4.12% premarket after Eisai and Biogen's Alzheimer's drug LEQEMBI shows sustained long-term benefits.

Iovance Biotherapeutics, Inc. rose 4.12% in premarket trading. The company's stock price increase is likely due to the positive news surrounding Eisai and Biogen's Alzheimer's drug LEQEMBI, which has shown sustained long-term effects against cognitive decline in Alzheimer's patients. The drug has demonstrated a 34% reduction in cognitive decline after four years of treatment, with no new safety concerns emerging over the extended period. This news is particularly relevant as it highlights the potential for long-term benefits and the approval of an injectable version of the drug, which can be administered at home.